✦ LIBER ✦

Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia

✍ Scribed by Steven M. Trifilio; Alfred W. Rademaker; Diane Newman; Katherine Coyle; Katrin Carlson-Leuer; Jayesh Mehta; Jessica Altman; Olga Frankfurt; Martin S. Tallman

Book ID: 113773598
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 180 KB
Volume: 36
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2011.10.027

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Single-dose mitoxantrone in combination

Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia

✍ Sung-Sook Lee; Je-Hwan Lee; Jung-Hee Lee; Dae-Young Kim; Se Hyung Kim; Sung-nam 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 146 KB

Mitoxantrone and Cytarabine Induction, H

Mitoxantrone and Cytarabine Induction, High-Dose Cytarabine, and Etoposide Intensification for Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia: Children's Cancer Group Study 2951

✍ Wells, R. J. 📂 Article 📅 2003 🏛 American Society of Clinical Oncology 🌐 English ⚖ 302 KB

Successful treatment of adult acute lymp

Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy

✍ Noel Milpied; Christian Gisselbrecht; Jean-Luc Harousseau; Catherine Sebban; Fra 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 509 KB

Mitoxantrone, etoposide, and cytarabine

Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia : An Eastern Cooperative Oncology Group pilot study

✍ Martin S. Tallman; Sandra Lee; Branimir I. Sikic; Elisabeth Paietta; Peter H. Wi 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

## Background: One potential mechanism of drug resistance to chemotherapy is the overexpression of multidrug resistance (mdr) genes coding for p-glycoprotein (p-gp), which leads to reduced intracellular retention of chemotherapy. this study tested the efficacy and toxicity of mitoxantrone, etoposid

Efficacy and feasibility of cyclophospha

Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML)

✍ Schnetzke, Ulf; Fix, Peter; Spies-Weisshart, Baerbel; Schrenk, Karin; Glaser, An 📂 Article 📅 2014 🏛 Springer-Verlag 🌐 English ⚖ 268 KB

Idarubicin in combination with intermedi

Idarubicin in combination with intermediate-dose cytarabine in the treatment of refractory or relapsed acute leukemias

✍ Angelo M. Carella; Ester Pungolino; Gabriella Piatti; Eugenia Gaozza; Sandro Nat 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 345 KB